These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

332 related articles for article (PubMed ID: 37533111)

  • 1. Update on histone deacetylase inhibitors in peripheral T-cell lymphoma (PTCL).
    Lu G; Jin S; Lin S; Gong Y; Zhang L; Yang J; Mou W; Du J
    Clin Epigenetics; 2023 Aug; 15(1):124. PubMed ID: 37533111
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New directions in treating peripheral T-cell lymphomas (PTCL): leveraging epigenetic modifiers alone and in combination.
    Ma H; O'Connor OA; Marchi E
    Expert Rev Hematol; 2019 Mar; 12(3):137-146. PubMed ID: 30782038
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting histone deacetylases in T-cell lymphoma.
    Moskowitz AJ; Horwitz SM
    Leuk Lymphoma; 2017 Jun; 58(6):1306-1319. PubMed ID: 27813438
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An overview of investigational Histone deacetylase inhibitors (HDACis) for the treatment of non-Hodgkin's lymphoma.
    Apuri S; Sokol L
    Expert Opin Investig Drugs; 2016 Jun; 25(6):687-96. PubMed ID: 26954526
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Histone Deacetylase Inhibitors for Peripheral T-Cell Lymphomas.
    Irimia R; Piccaluga PP
    Cancers (Basel); 2024 Sep; 16(19):. PubMed ID: 39409979
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined oral 5-azacytidine and romidepsin are highly effective in patients with PTCL: a multicenter phase 2 study.
    Falchi L; Ma H; Klein S; Lue JK; Montanari F; Marchi E; Deng C; Kim HA; Rada A; Jacob AT; Kinahan C; Francescone MM; Soderquist CR; Park DC; Bhagat G; Nandakumar R; Menezes D; Scotto L; Sokol L; Shustov AR; O'Connor OA
    Blood; 2021 Apr; 137(16):2161-2170. PubMed ID: 33171487
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of new agents for peripheral T-cell lymphoma.
    Ito Y; Makita S; Tobinai K
    Expert Opin Biol Ther; 2019 Mar; 19(3):197-209. PubMed ID: 30658046
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic options in relapsed or refractory peripheral T-cell lymphoma.
    Coiffier B; Federico M; Caballero D; Dearden C; Morschhauser F; Jäger U; Trümper L; Zucca E; Gomes da Silva M; Pettengell R; Weidmann E; d'Amore F; Tilly H; Zinzani PL
    Cancer Treat Rev; 2014 Oct; 40(9):1080-8. PubMed ID: 25199959
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hematopoietic Cell Transplantation and Adoptive Cell Therapy in Peripheral T Cell Lymphoma.
    Rogers AM; Brammer JE
    Curr Hematol Malig Rep; 2020 Aug; 15(4):316-332. PubMed ID: 32529515
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Belinostat for the treatment of peripheral T-cell lymphomas.
    McDermott J; Jimeno A
    Drugs Today (Barc); 2014 May; 50(5):337-45. PubMed ID: 24918834
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Belinostat for the treatment of relapsed or refractory peripheral T-cell lymphoma.
    Campbell P; Thomas CM
    J Oncol Pharm Pract; 2017 Mar; 23(2):143-147. PubMed ID: 26921086
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Results from a multicenter, open-label, pivotal phase II study of chidamide in relapsed or refractory peripheral T-cell lymphoma.
    Shi Y; Dong M; Hong X; Zhang W; Feng J; Zhu J; Yu L; Ke X; Huang H; Shen Z; Fan Y; Li W; Zhao X; Qi J; Huang H; Zhou D; Ning Z; Lu X
    Ann Oncol; 2015 Aug; 26(8):1766-71. PubMed ID: 26105599
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Belinostat for the treatment of relapsed or refractory peripheral T-cell lymphoma.
    Rashidi A; Cashen AF
    Future Oncol; 2015; 11(11):1659-64. PubMed ID: 26043217
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Peripheral T-cell lymphoma.
    Foss FM; Zinzani PL; Vose JM; Gascoyne RD; Rosen ST; Tobinai K
    Blood; 2011 Jun; 117(25):6756-67. PubMed ID: 21493798
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Belinostat in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results of the Pivotal Phase II BELIEF (CLN-19) Study.
    O'Connor OA; Horwitz S; Masszi T; Van Hoof A; Brown P; Doorduijn J; Hess G; Jurczak W; Knoblauch P; Chawla S; Bhat G; Choi MR; Walewski J; Savage K; Foss F; Allen LF; Shustov A
    J Clin Oncol; 2015 Aug; 33(23):2492-9. PubMed ID: 26101246
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Belinostat: first global approval.
    Poole RM
    Drugs; 2014 Sep; 74(13):1543-54. PubMed ID: 25134672
    [TBL] [Abstract][Full Text] [Related]  

  • 17. T follicular helper phenotype predicts response to histone deacetylase inhibitors in relapsed/refractory peripheral T-cell lymphoma.
    Ghione P; Faruque P; Mehta-Shah N; Seshan V; Ozkaya N; Bhaskar S; Yeung J; Spinner MA; Lunning M; Inghirami G; Moskowitz A; Galasso N; Ganesan N; van der Weyden C; Ruan J; Prince HM; Trotman J; Advani R; Dogan A; Horwitz S
    Blood Adv; 2020 Oct; 4(19):4640-4647. PubMed ID: 33002132
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of Chemotherapy Combined With Chidamide Versus Chemotherapy in the Frontline Treatment for Peripheral T-Cell Lymphoma.
    Wang J; Su N; Fang Y; Ma S; Zhang Y; Cai J; Zou Q; Tian X; Xia Y; Liu P; Li Z; Huang H; Huang H; Cai Q
    Front Immunol; 2022; 13():835103. PubMed ID: 35185926
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New drug therapies in peripheral T-cell lymphoma.
    Howman RA; Prince HM
    Expert Rev Anticancer Ther; 2011 Mar; 11(3):457-72. PubMed ID: 21417858
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel therapies in peripheral T-cell lymphomas.
    O'Leary HM; Savage KJ
    Curr Hematol Malig Rep; 2008 Oct; 3(4):213-20. PubMed ID: 20425468
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.